The results of this Japanese subpopulation analysis indicate that, compared to NSAI alone, abemaciclib-NSAI combination therapy improved clinical outcomes with an acceptable safety profile when used as an initial treatment in postmenopausal women with advanced, ET-resistant HR+, HER2− breast cancer. The gene discussed is HR; the disease is breast carcinoma.